Section 1498 in Pharmaceutical Patent Litigation: The Overlooked But Stronger Sister to March-In Rights

March 2026

Abstract

Few statutory provisions have generated as much controversy in the pharmaceutical space as the federal government’s retained authority to override patent rights in the public interest. While patent exclusivity is often described as absolute, Congress has long preserved mechanisms that allow the government intervention in certain limited circumstances. Two such tools, Bayh-Dole’s march-in rights and 28 U.S.C. § 1498, sit at the intersection of innovation policy, public funding, and drug pricing. Each was enacted for different historical reasons and each reflects a distinct theory of how patent rights should operate when federal interests are implicated. Yet both now occupy center stage in debates over affordability, access to medicines, and the role of government in pharmaceutical patent enforcement.

Subscribe to reador

Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more

Joanna Brougher

Owner & Principal, BioPharma Law Group PLLC, USA

Orange Book Listings Under Scrutiny: What’s In, What’s Out, and Why It Matters

The Food and Drug Administration’s (FDA) Orange Book, officially titled Approved Drug Products with Therapeutic Equivalence Evaluations, plays a key role in the U.S. pharmaceutical patent and exclusivity system. The...Read more

Joanna Brougher

Owner & Principal, BioPharma Law Group PLLC, USA

REMS Patents: Listability and Other Issues

Abstract: Are Risk Evaluation and Mitigation Strategy (REMS) patents Orange Book listable (or even should be)? A straightforward question with a lot of disagreement. This paper discusses recent litigation on...Read more

Section 1498 in Pharmaceutical Patent Litigation: The Overlooked But Stronger Sister to March-In Rights

Abstract

Related Papers